SCHEMBL231627

SCHEMBL231627

O=C(O)Cc1ccc(O)c([N+](=O)[O-])c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.59
TSHR P16473 3/20 0.59
GAA P10253 3/20 0.59
KDM4E B2RXH2 3/20 0.59
POLB P06746 2/20 0.59
HPGD P15428 2/20 0.59
HSD17B10 Q99714 2/20 0.59
NFKB1 P19838 2/20 0.59
TDP1 Q9NUW8 2/20 0.59
LMNA P02545 2/20 0.59
RGS12 O14924 1/20 0.59
APEX1 P27695 1/20 0.59
THPO P40225 1/20 0.59
BLM P54132 1/20 0.59
GNAI1 P63096 1/20 0.59
PMP22 Q01453 1/20 0.59
HIF1A Q16665 1/20 0.59
CA2 P00918 2/20 0.54
MAPK1 P28482 2/20 0.53
ALDH1A1 P00352 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2710180 1.00 MAPT (0.59) MAPTTSHRGAAKDM4EPOLB
Nitric Acid SCHEMBL7984255 0.97 MAPT (0.56) MAPTTSHRGAAKDM4EPOLB
SCHEMBL7564083 0.88 POLB (0.52) MAPTTSHRGAAKDM4EPOLB
SCHEMBL6379699 0.86 GAA (0.59) MAPTTSHRGAAKDM4EPOLB
SCHEMBL2434953 0.86 GAA (0.59) MAPTTSHRGAAKDM4EPOLB
SCHEMBL1865824 0.86 CASP6 (0.55) MAPTTSHRGAAKDM4EPOLB
SCHEMBL2742575 0.85 MAPT (0.58) MAPTTSHRKDM4EPOLBHPGD
SCHEMBL13520189 0.85 POLB (0.52) MAPTTSHRKDM4EPOLBHPGD
SCHEMBL7126615 0.85 POLB (0.52) MAPTTSHRKDM4EPOLBHPGD
SCHEMBL3533309 0.83 POLB (0.51) MAPTTSHRKDM4EPOLBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 496 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4661890-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS Purdue Research Foundation (US) 2025-12-17 EP claimed
WO-2025085675-A1 CONJUGATES, COMPOSITIONS AND METHODS FOR TREATING RSV INFECTION NIEDRAUER MARY LYNN (US) 2025-04-24 WO claimed
WO-2025085664-A1 CONJUGATES, COM POSITIONS AND METHODS FOR TREATING INFLUENZA NIEDRAUER MARY LYNN (US) 2025-04-24 WO claimed
WO-2024167565-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS PURDUE RESEARCH FOUNDATION (US) 2024-08-15 WO claimed
US-10072043-B2 Inhibitors of protein tyrosine phosphatases INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2018-09-11 US claimed
US-20160176922-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES Indiana University Research and Technology Corpora tion (US) 2016-06-23 US claimed
US-9217012-B2 Inhibitors of protein tyrosine phosphatases INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2015-12-22 US claimed
US-20120088720-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATI (US) 2012-04-12 US claimed
WO-2010118241-A2 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) 2010-10-14 WO claimed
WO-1998008875-A1 NOVEL COMBINATION PREPARATIONS AND THEIR USE IN IMMUNODIAGNOSIS AND IMMUNOTHERAPY VIVA DIAGNOSTIKA DIAGNOSTISCHE PRODUKTE GMBH (DE) 1998-03-05 WO claimed
EP-0815872-A2 Compounds for targeting IMPERIAL CANCER RESEARCH TECHNOLOGY LIMITED (GB) 1998-01-07 EP claimed
EP-0679094-A1 COMPOUNDS FOR TARGETING IMPERIAL CANCER RESEARCH TECHNOLOGY LIMITED (GB) 1995-11-02 EP claimed
WO-1994015644-A1 COMPOUNDS FOR TARGETING IMPERIAL CANCER RESEARCH TECHNOLOGY LIMITED (GB) 1994-07-21 WO claimed
JP-6277046-A None JP disclosed
WO-2026106497-A2 FUNCTIONALIZED CIRCULAR RNA AND METHODS AND INTERMEDIATES FOR THEIR PRODUCTION SIEĆ BADAWCZA ŁUKASIEWICZ – PORT POLSKI OSRODEK ROZWOJU TECHNOLOGII (PL) 2026-05-21 WO disclosed
CN-122055148-A Conjugates, compositions and methods for treating influenza 珀杜研究基金会 2026-05-15 CN disclosed
US-4415751-A Process for preparing phenylalkanoic acids ELI LILLY AND COMPANY (US) 1983-11-15 US disclosed
EP-0089805-A2 Process for preparing phenylalkanoic acids ELI LILLY AND COMPANY (US) 1983-09-28 EP disclosed
EP-0081321-A1 2-Aminophenol derivatives ONO PHARMACEUTICAL CO., LTD. (JP) 1983-06-15 EP disclosed
EP-0062440-A1 Process for preparing phenylalkanoic acids and derivatives of benzoxazole therefrom ELI LILLY AND COMPANY (US) 1982-10-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10072043-B2 Inhibitors of protein tyrosine phosphatases PTPRCAP, PTPRF, PTPRS MAPT 2153/4885TSHR 1605/4885GAA 360/4885
US-20160176922-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES PTPRCAP, PTPRF, PTPRS MAPT 2153/4885TSHR 1605/4885GAA 360/4885
US-20120088720-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES PTPRCAP, PTPRF, PTPRS MAPT 2153/4885TSHR 1605/4885GAA 360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.